Follow the entities shaping the evidence.

…); −2.5 (IQR:(−5.75)-0) for rimegepant and −2 (IQR:(−12)-0) for atogepant. A ≥50% MMDw9–12 reduction was achieved by 25% overall, 25% wit…

…ary paediatric hospital, who met SOS risk criteria and received defibrotide prophylaxis.Material and Methods Retrospective cohort of paedia…

… treat endogenous Cushing’s syndrome, drugs such as metyrapone, ketoconazole, and osilodrostat are available to control hypercortisolism. In…

…eceived 150mg/12h, and 3% received 75mg/12h. The indication for idarucizumab use was: 56% uncontrolled bleeding, 34% emergency surgery, 7% d…

… immunomodulation with combination targeted biologics—including eculizumab—may achieve full end-organ recovery despite life-threatening im…

…rythematosus (SLE), mixed connective tissue disease (MCTD), and antiphospholipid syndrome (APS) followed at two tertiary care centers in Denmark during 2…

…11), antimalarials (n= 55), tacrolimus (n= 27), everolimus (1), belimumab (BLM) (19) and anifrolumab (1). After a follow-up of 59.7±46 mo…

…on (IFN) pathway activation and myeloid- and B-cell activation. Enpatoran is a novel, first-in-class, oral TLR7/8 inhibitor. In a Phase 2…

…n the pre-competitive setting, the most pressing impediments to lupus drug development. Here, we provide an update on the impactful a…

…licated autoimmune disease characterized by recurrent relapses. Belimumab (BEL) is a humanized monoclonal antibody and has been approved …

…using data from the phase 3 PHOENYCS GO trial ( NCT04294667) of dapirolizumab pegol (DZP).DZP, a novel CD40L inhibitor, consists of a polyethylene …

…up is warranted to confirm these findings.Clinical implications Cannabis use in older adults does not appear linked to faster cognitive …